Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LataMed AILMEDD +13.78%26 ROE % is -6.51% as of Mar. 2026. GuruFocus rates LMEDD with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 2,683 Software companies, LataMed AI ranks worse than 81.25% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. LataMed AI's annualized net income for the quarter that ended in Mar. 2026 was $-0.21 Mil. LataMed AI's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $3.25 Mil. Therefore, LataMed AI's annualized ROE % for the quarter that ended in Mar. 2026 was -6.51%.
The historical rank and industry rank for LataMed AI's ROE % or its related term are showing as below:
LMEDD'
s ROE % Range Over the Past 10 Years
Min: -25.54 Med: 0 Max: 0
Current: -25.54
LMEDD's ROE % is ranked worse than 81.25% of 2683
companies
in the Software industry
Industry Median: 4.74
vs LMEDD: -25.54
LataMed AI (OTCPK:LMEDD) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
LataMed AI ROE % Related Terms
LataMed AI ROE % Historical Data
* Premium members only.
The historical data trend for LataMed AI's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Application subindustry, LataMed AI's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LataMed AI ROE % vs Software Industry
For the Software industry and Technology sector, LataMed AI's ROE % distribution charts can be found below:
* The bar in red indicates where LataMed AI's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
LataMed AI (LMEDD) has a ROE % of -6.51% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LataMed AI and its competitors. According to the industry distribution chart, LataMed AI ranks #2180 out of 2683 companies in the Software industry, placing it in the top 81.3%.
Is LataMed AI's ROE % too high?
LataMed AI's current ROE % is -6.51%. Based on the distribution chart, LataMed AI ranks #2180 out of 2683 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, LataMed AI has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does LataMed AI's ROE % compare to KLTR and BZAI?
According to the Software industry distribution chart, LataMed AI ranks #2180 out of 2683 companies for ROE %. This places LataMed AI in the lower half of its industry. The industry median ROE % is 4.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Software company?
The median ROE % among Software companies is 4.74, based on 2,683 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LataMed AI and its competitors. For the Software industry, the median ROE % is 4.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LataMed AI's current ROE % is -6.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LataMed AI stock overvalued right now?
LataMed AI (LMEDD) has a current ROE % of -6.51%. The current ROE % is -6.51%. LataMed AI's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For LataMed AI (LMEDD), the current ROE % is -6.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America. Its healthcare platform includes AI-enabled analytics, telehealth infrastructure, and coordinated care systems designed to support healthcare delivery in emerging markets. The company develops digital infrastructure for patient prioritization, clinical workflow management, telehealth access, care coordination, and healthcare system operations. It holds issued patents for its core AI modules-CardioAI, PulmoAI, and NeuroAI-which deliver predictive analytics for cardiovascular, pulmonary, and neurological disease detection and management.
26GF Score
Get the complete analysis for LMEDD
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMEDD has been successfully added to your 
